𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Retroviral integrase inhibitors year 2000: update and perspectives

✍ Scribed by Yves Pommier; Christophe Marchand; Nouri Neamati

Book ID
114144105
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
134 KB
Volume
47
Category
Article
ISSN
0166-3542

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

HIV-1 integrase inhibitors: 2003–2004 up
HIV-1 integrase inhibitors: 2003–2004 update
✍ Raveendra Dayam; Jinxia Deng; Nouri Neamati πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 906 KB

## Abstract The integration of viral cDNA into the host genome is an essential step in the HIV‐1‐life cycle and is mediated by the virally encoded enzyme, integrase (IN). Inhibition of this process provides an attractive strategy for antiviral drug design. The discovery of β‐diketo acid inhibitors

HIV-1 integrase inhibitors: 2005–2006 up
HIV-1 integrase inhibitors: 2005–2006 update
✍ Raveendra Dayam; Rambabu Gundla; Laith Q. Al-Mawsawi; Nouri Neamati πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 813 KB

## Abstract HIV‐1 integrase (IN) catalyzes the integration of proviral DNA into the host genome, an essential step for viral replication. Inhibition of IN catalytic activity provides an attractive strategy for antiretroviral drug design. Currently two IN inhibitors, MK‐0518 and GS‐9137, are in adva

HIV-1 integrase inhibitors: 2007–2008 up
HIV-1 integrase inhibitors: 2007–2008 update
✍ Kavya Ramkumar; Erik Serrao; Srinivas Odde; Nouri Neamati πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 892 KB

In recent years, HIV-1 integrase (IN) has become an attractive target for designing antiretroviral agents. The first IN inhibitor approved for clinical use, raltegravir, has validated the pharmacological viability of IN inhibitors and signals the advent of a new generation of antiretroviral drugs. T